SEPARATION AND RELEASE AGREEMENTSeparation and Release Agreement • March 18th, 2013 • Coronado Biosciences Inc • Pharmaceutical preparations • New York
Contract Type FiledMarch 18th, 2013 Company Industry JurisdictionThis SEPARATION AND RELEASE AGREEMENT (the “Agreement”) is made and entered into this 28th day of December, 2012 by and between Glenn L. Cooper, M.D. (“Cooper”) and Coronado Biosciences, Inc., a Delaware corporation (the “Company”).
SECOND AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2013 • Coronado Biosciences Inc • Pharmaceutical preparations
Contract Type FiledMarch 18th, 2013 Company IndustryThis SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”) is dated December 28, 2012 by and between CORONADO BIOSCIENCES, INC., a Delaware corporation (the “Company”), and BOBBY W. SANDAGE JR. (the “Executive”). Unless the context otherwise requires, capitalized terms used herein shall have the meanings set forth in the Employment Agreement (as defined below) and in this Amendment.
EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2013 • Coronado Biosciences Inc • Pharmaceutical preparations • New York
Contract Type FiledMarch 18th, 2013 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is executed and dated January 7, 2013 and effective as of December 28, 2012, by and between Coronado Biosciences, Inc., a Delaware corporation (the “Company”), and Harlan F. Weisman, M.D. (the “Executive”).
SECOND AMENDMENT AND AGREEMENTExclusive Sublicense Agreement • March 18th, 2013 • Coronado Biosciences Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledMarch 18th, 2013 Company Industry JurisdictionTHIS SECOND AMENDMENT AND AGREEMENT (“Second Amendment”) is made as of December 21, 2012 (“Second Amendment Effective Date”) by and between Coronado Biosciences Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 24 New England Executive Park, Burlington, MA 01803, United States (“Coronado”) and Ovamed GmbH, a company with limited liability organized and existing under the laws of Germany and having its principal office at Kiebitzhörn 31, 22885 Barsbüttel, Germany (“Ovamed”). Coronado and Ovamed are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.